Patents by Inventor Irving Weissman

Irving Weissman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050191284
    Abstract: A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for lymphoid lineages, but lacking the potential to differentiate into myeloid and erythroid lineages. Methods are provided for the isolation and culture of this common lymphoid progenitor cell (CLP). The cell enrichment methods employ reagents that specifically recognize CDw127 (IL-7 receptor ?); CD117 (c-kit) protein, in conjunction with other markers expressed on lineage committed cells. The murine cells are also characterized as expressing low levels of sca-1 (Ly-6E and Ly-6A). The CLPs are predominantly cycling, blast cells. These cells give rise to B cells, T cells and natural killer cells, as evidenced by their growth and differentiation in vitro and in vivo.
    Type: Application
    Filed: March 29, 2005
    Publication date: September 1, 2005
    Inventors: Koichi Akashi, Irving Weissman, Motonari Kondo
  • Publication number: 20050176142
    Abstract: A substantially enriched mammalian hematopoietic cell population is provided, which is characterized as a progenitor cell committed to the megakaryocyte lineage. Methods are provided for the isolation and culture of these cells. The cell enrichment methods employ reagents that specifically recognize CD9 and CD41, in conjunction with other markers expressed on lineage committed progenitor cells. These cells give rise exclusively to megakaryocytes and platelets, as evidenced by their growth and differentiation in vitro and in vivo.
    Type: Application
    Filed: September 12, 2003
    Publication date: August 11, 2005
    Inventors: Thanyaphong Nakorn, Toshihiro Miyamoto, Irving Weissman
  • Publication number: 20040171559
    Abstract: Reagents that block the extracellular activation of &bgr;-catenin are used to induce quiescence in normal stem cells, in order to reduce the killing of stem cells by anti-proliferative agents.
    Type: Application
    Filed: December 5, 2003
    Publication date: September 2, 2004
    Inventors: Irving Weissman, Tannishtha Reya
  • Publication number: 20040018531
    Abstract: Methods and compositions are provided for the identification of stem cells and cancer stem cells. &bgr;-catenin is also identified as a target for the development of therapeutic moieties against hematopoietic tumors, i.e. leukemia and lymphoma cells, which may include screening assays directed at &bgr;-catenin, or members of the &bgr;-catenin signaling pathway. Cellular proliferation in hematopoietic cells can be altered by introducing stabilized &bgr;-catenin into a hematopoietic cell that is altered in its ability to undergo apoptosis but which is not fully transformed. The immortalized cells are useful in screening assays, and in the analysis of pathways by which hematopoietic cells undergo transformation.
    Type: Application
    Filed: May 30, 2003
    Publication date: January 29, 2004
    Inventors: Catriona Helen M. Jamieson, Laurie Elizabeth Ailles, Tannishtha Reya, Irving Weissman
  • Publication number: 20030109039
    Abstract: Enriched neural stem and progenitor cell populations, and methods for identifying, isolating and enriching for neural stem cells using reagent that bind to cell surface markers, are provided.
    Type: Application
    Filed: July 11, 2002
    Publication date: June 12, 2003
    Inventors: David W. Buck, Nobuko Uchida, Irving Weissman
  • Patent number: 6468794
    Abstract: Enriched neural stem and progenitor cell populations, and methods for identifying, isolating and enriching for neural stem cells using reagent that bind to cell surface markers, are provided.
    Type: Grant
    Filed: October 21, 1999
    Date of Patent: October 22, 2002
    Assignee: StemCells, Inc.
    Inventors: Nobuko Uchida, David W. Buck, Irving Weissman
  • Publication number: 20020031792
    Abstract: Enriched neural stem and progenitor cell populations, and methods for identifying, isolating and enriching for neural stem cells using reagent that bind to cell surface markers, are provided.
    Type: Application
    Filed: August 9, 2001
    Publication date: March 14, 2002
    Inventors: Nobuko Uchida, David W. Buck, Irving Weissman
  • Publication number: 20010044122
    Abstract: Enriched neural stem and progenitor cell populations, and methods for identifying, isolating and enriching for neural stem cells using reagent that bind to cell surface markers, are provided.
    Type: Application
    Filed: February 23, 2001
    Publication date: November 22, 2001
    Inventors: David W. Buck, Nobuko Uchida, Irving Weissman
  • Patent number: 5928638
    Abstract: The present invention provides a method for optimizing gene transfer into hematopoietic stem cells (HSCs) by contacting the cells with hydroxyurea prior to gene transfer to induce HSCs in G0 into active cell cycle. This method is useful for treating patients suffering from a disease that is suitably treated by gene therapy or involves hematopoietic cells. A method is also provided for enhancing the efficacy of bone marrow transplantation by administering hydroxyurea to increase HSC yields.
    Type: Grant
    Filed: June 17, 1996
    Date of Patent: July 27, 1999
    Assignee: SyStemix, Inc.
    Inventors: Nobuko Uchida, Ann Tsukamoto, Irving Weissman
  • Patent number: 5914108
    Abstract: Human hematopoietic stem cells are provided by separation of the stem cells from dedicated cells. The stem cells may than be maintained by regeneration in an appropriate growth medium. Means are provided for assaying for the stem cells as to their capability for producing members of each of the hematopoietic lineages. A method for treating a human by implanting a cellular composition comprising greater than 90% human hematopoietic stem cells is also disclosed.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 22, 1999
    Assignee: Systemix, Inc.
    Inventors: Ann Tsukamoto, Charles M. Baum, Yukoh Aihara, Irving Weissman
  • Patent number: 5821108
    Abstract: A subpopulation in the CD4.sup.+ 8.sup.+ (DP) thymic blast population is identified that is the precursor for thymic T cells. All such progenitors are c-kit.sup.+. The c-kit.sup.+ subset expresses lower levels of CD4 and CD8 than the large and small DP c-kit- cells. These DP.sup.int c-kit.sup.+ cells differentiate to thymic T cells rapidly on heterogenous thymic stromal cell cultures. Similar maturation takes place in vivo over 4 days. A method for isolating the cells which are c-kit.sup.+ and which express intermediate or low levels of CD4+/CD8+ is also disclosed.
    Type: Grant
    Filed: April 7, 1995
    Date of Patent: October 13, 1998
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Koichi Akashi, Irving Weissman
  • Patent number: 5763197
    Abstract: Human hematopoietic stem cells are provided by separation of the stem cells from dedicated cells. The stem cells may than be maintained by regeneration in an appropriate growth medium. Means are provided for assaying for the stem cells as to their capability for producing members of each of the hematopoietic lineages.
    Type: Grant
    Filed: June 25, 1991
    Date of Patent: June 9, 1998
    Assignee: Systemix, Inc.
    Inventors: Ann Tsukamoto, Charles M. Baum, Yukoh Aihara, Irving Weissman
  • Patent number: 5750397
    Abstract: Human hematopoietic stem cells are provided by separation of the stem cells from dedicated cells. The stem cells may than be maintained by regeneration in an appropriate growth medium. Means are provided for assaying for the stem cells as to their capability for producing members of each of the hematopoietic lineages.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: May 12, 1998
    Assignee: Systemix, Inc.
    Inventors: Ann Tsukamoto, Charles M. Baum, Yukoh Aihara, Irving Weissman
  • Patent number: 5716827
    Abstract: Human hematopoietic stem cells are provided by separation of the stem cells from dedicated cells. The stem cells may than be maintained by regeneration in an appropriate growth medium. Means are provided for assaying for the stem cells as to their capability for producing members of each of the hematopoietic lineages.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 10, 1998
    Assignee: SyStemix, Inc.
    Inventors: Ann Tsukamoto, Charles M. Baum, Yukoh Aihara, Irving Weissman
  • Patent number: 5643741
    Abstract: Human hematopoietic stem cells are identified according to expression of specific cell surface markers. Substantially homogenous stem cell compositions are obtained by selective isolation of cells free of markers associated with differentiated cells, while displaying epitopic characteristics associated with the stem cells. The stem cells may then be maintained by regeneration in an appropriate growth medium. Means are provided for assaying for the stem cells as to their capability for producing members of each of the hematopoietic lineages.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 1, 1997
    Assignee: Systemix, Inc.
    Inventors: Ann Tsukamoto, Charles M. Baum, Yukoh Aihara, Irving Weissman
  • Patent number: 5614397
    Abstract: Methods and compositions for modifying the lifespan of progeny cells of mammalian hematopoietic stem cells, particularly myeloid series cells, are provided. Transgenic nonhuman mammals also are provided which produce transgenic myeloid cells having an altered lifespan.
    Type: Grant
    Filed: February 22, 1994
    Date of Patent: March 25, 1997
    Assignee: Board of Trustees of the Leland Stanford Junior University
    Inventors: Irving Weissman, Eric Lagasse
  • Patent number: 5061620
    Abstract: Human hematopoietic stem cells are provided by separation of the stem cells from dedicated cells. The stem cells may than be maintained by regeneration in an appropriate growth medium. Means are provided for assaying for the stem cells as to their capability for producing members of each of the hematopoietic lineages.
    Type: Grant
    Filed: March 30, 1990
    Date of Patent: October 29, 1991
    Assignee: SyStemix, Inc.
    Inventors: Ann Tsukamoto, Charles M. Baum, Yukoh Aihara, Irving Weissman